Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665440 | 0.85 | HSD17B13 (0.45) | HSD17B13ATRNAMPTHPGDMAPT | |
| SCHEMBL1665449 | 0.81 | SMN1; SMN2 (0.56) | RXFP1MAPTGRM4TYK2EPHB3 | |
| SCHEMBL1024530 | 0.78 | P2RX1 (0.47) | HSD17B13JAK2TYK2 | |
| SCHEMBL1666251 | 0.78 | NPC1 (0.65) | JAK2TYK2KDR | |
| SCHEMBL11557556 | 0.77 | PYGL (0.47) | HSD17B13ATRNAMPTPYGLMAPT | |
| SCHEMBL12172753 | 0.75 | KMT2A (0.67) | RXFP1PYGL | |
| SCHEMBL16127846 | 0.74 | RXFP1 (0.56) | RXFP1TSHRMAPT | |
| SCHEMBL15391362 | 0.73 | MLYCD (0.57) | NAMPTTSHRCYP1A2HPGDCYP2C19 | |
| SCHEMBL28072777 | 0.73 | JAK2 (0.67) | NAMPTCYP11B2GRM4JAK2TYK2 | |
| SCHEMBL16180129 | 0.72 | IRAK4 (0.74) | JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486035-B1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8742112-B2 | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| CN-102686585-A | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL CO | 2012-09-19 | — | — | CN | disclosed |
| EP-2486035-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | Sumitomo Chemical Co., Ltd (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2011043404-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | HAAO, DDT, ACHE | HSD17B13 1334/4885ATR 704/4885NAMPT 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.